Compare S&P500 ETF (SPY) vs Viatris Inc (VTRS) Price & Performance

S&P500 ETFTrade

Viatris IncTrade

Price performance (Past 24H)

Key statistics

S&P500 ETF vs Viatris Inc — how do they compare? S&P500 ETF trades at $764.05, while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc pays a 2.89% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals.

	SPY	VTRS
52-Week High	$777.82	$17.86
52-Week Low	$631.99	$9.49
Market Cap	—	$19.09B
Sector	—	Health
Enterprise Value	—	$31.21B
Dividend Yield	—	2.89%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

S&P500 ETF

SPY trades at $766.00, down 0.55% on the day, with a neutral technical signal and bullish moving averages. Support levels are near $760, while resistance sits at $769. The ETF shows no available valuation ratios like P/E or P/B in the data. A dividend of $1.90 is scheduled for payment on July 31, 2026.

Outlook remains mixed amid market volatility from geopolitical tensions and oil price surges. Risks include Fed rate-hike concerns and high valuations, but AI-driven earnings growth offers potential upside. Investors should weigh resilience against near-term headwinds for long-term positioning.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

SPY

Memory chip stocks rise as Goldman Sachs says sector's worst downturn may be over.24/7 Wall Street · 21 hours agoBullish S&P 500 set to rebound with 8,000 target despite rising rates, driven by strong earnings growth.Seeking Alpha · 21 hours agoBullish Safe bond funds lost money over 5 years, showing cautious investing can be risky for young investors.24/7 Wall Street · 21 hours agoNeutral View details →

VTRS

Viatris Q2 earnings rise 11%, free cash flow doubles, boosting shareholder returns and growth outlook.Seeking Alpha · 17 hours agoBullish View details →

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).